Dual inhibition of HERs and PD-1 counteract resistance in KRAS G12C -mutant head and neck cancer

Basket clinical trials targeting the KRAS -mutation in solid tumors have shown initial promise, including in orphan KRAS head and neck cancer (HNC). However, development of resistance to KRAS -mutant-specific inhibitors (KRAS i) remains a major obstacle. Here, we investigated the intrinsic (tumor-ce...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of experimental & clinical cancer research 2024-11, Vol.43 (1), p.308
Hauptverfasser:	Novoplansky, Ofra, Jagadeeshan, Sankar, Prasad, Manu, Yegodayev, Ksenia M, Marripati, Divyasree, Shareb, Raghda Abu, Greenshpan, Yariv, Mathukkada, Sooraj, Ben-Lulu, Talal, Bhattacharya, Baisali, Porgador, Angel, Kong, Dexin, Brägelmann, Johannes, Gutkind, J Silvio, Elkabets, Moshe
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cell Line, Tumor Drug Resistance, Neoplasm Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - genetics Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - pathology Humans Mice Mutation Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - metabolism Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!